Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2010

01-04-2010 | Editorial

Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy

Authors: Joseph A. Sparano, Etta D. Pisano, Julia R. White, Kelly K. Hunt, Eleftherios P. Mamounas, Edith A. Perez, Gabriel N. Hortobagyi, Julie R. Gralow, Robert L. Comis

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Login to get access

Abstract

Imaging and local therapy are important modalities for detection and management of localized breast cancer. Improvements in screening and local therapy have contributed to reduced breast cancer-associated morbidity and mortality. The Coalition of Cancer Cooperative Groups (CCCG) convened the Scientific Leadership Council (SLC) in breast cancer, an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for breast imaging and locoregional therapy, and also identified six trials judged to be of high priority. Current high priority trials included trials determining: (1) the role of accelerated partial breast versus whole-breast radiation (B39), (2) the feasibility, safety, and local and systemic control of small localized breast cancers treated with tumor ablation (Z1072), (3) the role of removal of the primary cancer in selected patients with metastatic disease (E2108), and (4) the clinical and biological effects of pre-operative anti-HER2-directed and ER-directed therapies in localized or locally advanced breast cancer (B41, Z1031, Z1041). Ongoing and future trials will further refine optimal locoregional management, and additional research is required to develop improved screening methods and identify high risk populations most likely to benefit from targeted screening.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society (2007) Breast cancer facts and figures 2007–2008. American Cancer Society, Inc, Atlanta
2.
Stewart SL, King JB, Thompson TD et al (2004) Cancer mortality surveillance—United States, 1990–2000. MMWR Surveill Summ 53:1–108PubMed
3.
Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792CrossRefPubMed
4.
Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674CrossRefPubMed
5.
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed
6.
7.
Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL (2009) Recommendations for research priorities in breast cancer by the coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. Breast Cancer Res Treat. doi:10.​1007/​s10549-009-0433-y
8.
Kerlikowske K, Grady D, Rubin SM et al (1995) Efficacy of screening mammography. A meta-analysis. JAMA 273:149–154CrossRefPubMed
9.
Hendrick RE, Smith RA, Rutledge JH III et al (1997) Benefit of screening mammography in women aged 40–49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 22:87–92PubMed
10.
Kopans DB (2003) Mammographic screening for breast cancer. N Engl J Med 349:610–612 (author reply 610–612)CrossRefPubMed
11.
Kopans DB, Feig SA (1998) False positive rate of screening mammography. N Engl J Med 339:562–564PubMed
12.
Centers for Disease Control, Prevention (2007) Use of mammograms among women aged > or = 40 years—United States 2000–2005. MMWR Morb Mortal Wkly Rep 56:49–51
13.
Joy JE, Penhoet EE, Petitti DB (eds) (2004) Saving women’s lives: strategies for improving breast cancer detection and diagnosis. The National Academies Press, Washington, DC
14.
15.
Pisano ED, Acharyya S, Cole EB et al (2009) Cancer cases from ACRIN digital mammographic imaging screening trial: radiologist analysis with use of a logistic regression model. Radiology 252:348–357CrossRefPubMed
16.
Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773–1783CrossRefPubMed
17.
Tosteson AN, Stout NK, Fryback DG et al (2008) Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 148:1–10PubMed
18.
Jong RA, Yaffe MJ, Skarpathiotakis M et al (2003) Contrast-enhanced digital mammography: initial clinical experience. Radiology 228:842–850CrossRefPubMed
19.
Buchberger W, DeKoekkoek-Doll P, Springer P et al (1999) Incidental findings on sonography of the breast: clinical significance and diagnostic workup. AJR Am J Roentgenol 173:921–927PubMed
20.
Kaplan SS (2001) Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 221:641–649CrossRefPubMed
21.
Kolb TM, Lichy J, Newhouse JH (2002) Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27, 825 patient evaluations. Radiology 225:165–175CrossRefPubMed
22.
Lehman CD, Isaacs C, Schnall MD et al (2007) Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 244:381–388CrossRefPubMed
23.
Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325CrossRefPubMed
24.
Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K, ACRIN 6666 Investigators (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299(18):2151–2163
25.
Berg W (2007) Yield of screening breast ultrasound and mammography compared to mammography alone: results of first screen in ACRIN (American College of Radiology Imaging Network, the Radiological Society of North America (RSNA) 93rd Scientific Assembly and Annual Meeting. Chicago, Illinois
26.
Berg W (2007) Risk of false positives with supplemental screening breast US: results from the first screen in the ACRIN (American College of Radiology Imaging Network), the Radiological Society of North America (RSNA) 93rd Scientific Assembly and Annual Meeting. Chicago, Illinois
27.
Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437CrossRefPubMed
28.
Brekelmans CT, Seynaeve C, Bartels CC et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924–930PubMed
29.
Chart PL, Franssen E (1997) Management of women at increased risk for breast cancer: preliminary results from a new program. CMAJ 157:1235–1242PubMed
30.
Lalloo F, Boggis CR, Evans DG et al (1998) Screening by mammography, women with a family history of breast cancer. Eur J Cancer 34:937–940CrossRefPubMed
31.
Kuhl CK, Schrading S, Wardelmann E et al (2007) Magnetic resonance imaging versus mammography for diagnosing ductal carcinoma in situ. J Clin Oncol 25:1504 (suppl; abstr 1504)
32.
Lord SJ, Lei W, Craft P et al (2007) A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43:1905–1917CrossRefPubMed
33.
Lehman CD, Gatsonis C, Kuhl CK et al (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356:1295–1303CrossRefPubMed
34.
Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89CrossRefPubMed
35.
Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209CrossRefPubMed
36.
Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367CrossRefPubMed
37.
Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082–4088CrossRefPubMed
38.
Solin LJ, Orel SG, Hwang WT et al (2008) Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26:386–391CrossRefPubMed
39.
Bleicher RJ, Ciocca RM, Egleston BL et al (2009) Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 209:180–187 (quiz 294–295)CrossRefPubMed
40.
Berg WA, Weinberg IN, Narayanan D et al (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer. Breast J 12:309–323CrossRefPubMed
41.
Poplack SP, Tosteson TD, Kogel CA et al (2007) Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol 189:616–623CrossRefPubMed
42.
Vazquez B, Rousseau D, Hurd TC (2007) Surgical management of breast cancer. Semin Oncol 34:234–240CrossRefPubMed
43.
Morrow M (2007) Improved survival in metastatic breast cancer following total excision of the primary tumor. Nat Clin Pract Oncol 4(1):14–15
44.
Lee MC, Newman LA (2007) Management of patients with locally advanced breast cancer. Surg Clin North Am 87:379–398 (ix)CrossRefPubMed
45.
Haka AS, Volynskaya Z, Gardecki JA et al (2006) In vivo margin assessment during partial mastectomy breast surgery using Raman spectroscopy. Cancer Res 66:3317–3322CrossRefPubMed
46.
Bickford LR, Agollah G, Drezek R, Yu TK (2009) Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy. Breast Cancer Res Treat. doi:10.​1007/​s10549-009-0408-z
47.
Singletary SE, Fornage BD, Sneige N et al (2002) Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J 8:177–180CrossRefPubMed
48.
Waljee JF, Newman LA (2007) Neoadjuvant systemic therapy and the surgical management of breast cancer. Surg Clin North Am 87:399–415 (ix)CrossRefPubMed
49.
Oh JL, Nguyen G, Whitman GJ et al (2007) Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 110:2420–2427CrossRefPubMed
50.
Albertini JJ, Lyman GH, Cox C et al (1996) Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818–1822CrossRefPubMed
51.
Bedrosian I, Reynolds C, Mick R et al (2000) Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88:2540–2545CrossRefPubMed
52.
Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–398 (discussion 398–401)CrossRefPubMed
53.
Krag DN, Julian TB, Harlow SP et al (2004) NSABP-32: phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol 11:208S–210SPubMed
54.
McMasters KM, Tuttle TM, Carlson DJ et al (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560–2566PubMed
55.
O’Hea BJ, Hill AD, El-Shirbiny AM et al (1998) Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 186:423–427CrossRefPubMed
56.
Wong SL, Edwards MJ, Chao C et al (2002) The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 9:272–277CrossRefPubMed
57.
Newman LA, Mamounas EP (2007) Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surg Clin North Am 87:279–305 (vii)CrossRefPubMed
58.
Creager AJ, Geisinger KR, Perrier ND et al (2004) Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast. Ann Surg 239:61–66CrossRefPubMed
59.
Shiver SA, Creager AJ, Geisinger K et al (2002) Intraoperative analysis of sentinel lymph nodes by imprint cytology for cancer of the breast. Am J Surg 184:424–427CrossRefPubMed
60.
Creager AJ, Geisinger KR, Shiver SA et al (2002) Intraoperative evaluation of sentinel lymph nodes for metastatic breast carcinoma by imprint cytology. Mod Pathol 15:1140–1147CrossRefPubMed
61.
Blumencranz P, Whitworth PW, Deck K et al (2007) Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 194:426–432CrossRefPubMed
62.
Mamounas EP (2003) Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 83:931–942CrossRefPubMed
63.
Xing Y, Foy M, Cox DD et al (2006) Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93:539–546CrossRefPubMed
64.
Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106PubMed
65.
Patt DA, Goodwin JS, Kuo YF et al (2005) Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 23:7475–7482CrossRefPubMed
66.
Giordano SH, Kuo YF, Freeman JL et al (2005) Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419–424PubMedCrossRef
67.
Sanders ME, Scroggins T, Ampil FL et al (2007) Accelerated partial breast irradiation in early-stage breast cancer. J Clin Oncol 25:996–1002CrossRefPubMed
68.
Fearmonti RM, Vicini FA, Pawlik TM et al (2007) Integrating partial breast irradiation into surgical practice and clinical trials. Surg Clin North Am 87:485–498 (x–xi)CrossRefPubMed
69.
Arthur DW, Winter K, Kuske RR et al (2008) A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of Rtog 95–17. Int J Radiat Oncol Biol Phys 72:467–473PubMed
70.
Vicini FA, Chen P, Wallace M et al (2007) Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 69:1124–1130PubMed
71.
Benitez PR, Keisch ME, Vicini F et al (2007) Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 194:456–462CrossRefPubMed
72.
Keisch M, Vicini F (2005) Applying innovations in surgical and radiation oncology to breast conservation therapy. Breast J 11(suppl 1):S24–S29CrossRefPubMed
73.
Donovan E, Bleakley N, Denholm E et al (2007) Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 82:254–264CrossRefPubMed
74.
Pignol JP, Olivotto I, Rakovitch E et al (2008) A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26:2085–2092CrossRefPubMed
75.
Harsolia A, Kestin L, Grills I et al (2007) Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68:1375–1380PubMed
76.
Bentzen SM, Agrawal RK, Aird EG et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371:1098–1107CrossRefPubMed
77.
Whelan T, MacKenzie R, Julian J et al (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94:1143–1150PubMed
78.
Freedman GM, Anderson PR, Goldstein LJ et al (2007) Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys 68:347–353PubMed
79.
Formenti SC, Gidea-Addeo D, Goldberg JD et al (2007) Phase I–II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 25:2236–2242CrossRefPubMed
80.
Jin JY, Klein EE, Kong FM et al (2005) An improved internal mammary irradiation technique in radiation treatment of locally advanced breast cancers. J Appl Clin Med Phys 6:84–93CrossRefPubMed
Metadata
Title
Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy
Authors
Joseph A. Sparano
Etta D. Pisano
Julia R. White
Kelly K. Hunt
Eleftherios P. Mamounas
Edith A. Perez
Gabriel N. Hortobagyi
Julie R. Gralow
Robert L. Comis
Publication date
01-04-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0655-z

Other articles of this Issue 2/2010

Breast Cancer Research and Treatment 2/2010 Go to the issue

Preclinical study

DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery

Review

Tai chi for breast cancer patients: a systematic review

Review

Adjuvant therapy of triple negative breast cancer

Preclinical study

Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

Invited Commentary

Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor

Clinical trial

Outcome of axillary staging in early breast cancer: a meta-analysis

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits